GB0207899D0 - Formoterol and cielesonide aerosol formulations - Google Patents

Formoterol and cielesonide aerosol formulations

Info

Publication number
GB0207899D0
GB0207899D0 GBGB0207899.6A GB0207899A GB0207899D0 GB 0207899 D0 GB0207899 D0 GB 0207899D0 GB 0207899 A GB0207899 A GB 0207899A GB 0207899 D0 GB0207899 D0 GB 0207899D0
Authority
GB
United Kingdom
Prior art keywords
sub
formoterol
cielesonide
aerosol formulations
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0207899.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Priority to GBGB0207899.6A priority Critical patent/GB0207899D0/en
Publication of GB0207899D0 publication Critical patent/GB0207899D0/en
Priority to CA002481187A priority patent/CA2481187A1/en
Priority to EP03746589A priority patent/EP1492500B1/en
Priority to DE60322200T priority patent/DE60322200D1/de
Priority to JP2003583372A priority patent/JP5198716B2/ja
Priority to AU2003262146A priority patent/AU2003262146A1/en
Priority to US10/510,147 priority patent/US20050207984A1/en
Priority to PCT/US2003/010285 priority patent/WO2003086349A1/en
Priority to AT03746589T priority patent/ATE401056T1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
GBGB0207899.6A 2002-04-05 2002-04-05 Formoterol and cielesonide aerosol formulations Ceased GB0207899D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0207899.6A GB0207899D0 (en) 2002-04-05 2002-04-05 Formoterol and cielesonide aerosol formulations
CA002481187A CA2481187A1 (en) 2002-04-05 2003-04-01 Formoterol and ciclesonide aerosol formulations
EP03746589A EP1492500B1 (en) 2002-04-05 2003-04-01 Formoterol and ciclesonide aerosol formulations
DE60322200T DE60322200D1 (de) 2002-04-05 2003-04-01 Formoterol und ciclesonid aerosol-formulierungen
JP2003583372A JP5198716B2 (ja) 2002-04-05 2003-04-01 フォルモテロールおよびシクレソニドのエアロゾル製剤
AU2003262146A AU2003262146A1 (en) 2002-04-05 2003-04-01 Formoterol and ciclesonide aerosol formulations
US10/510,147 US20050207984A1 (en) 2002-04-05 2003-04-01 Formoterol and ciclesonide aerosol formulations
PCT/US2003/010285 WO2003086349A1 (en) 2002-04-05 2003-04-01 Formoterol and ciclesonide aerosol formulations
AT03746589T ATE401056T1 (de) 2002-04-05 2003-04-01 Formoterol und ciclesonid aerosol-formulierungen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207899.6A GB0207899D0 (en) 2002-04-05 2002-04-05 Formoterol and cielesonide aerosol formulations

Publications (1)

Publication Number Publication Date
GB0207899D0 true GB0207899D0 (en) 2002-05-15

Family

ID=9934322

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0207899.6A Ceased GB0207899D0 (en) 2002-04-05 2002-04-05 Formoterol and cielesonide aerosol formulations

Country Status (9)

Country Link
US (1) US20050207984A1 (https=)
EP (1) EP1492500B1 (https=)
JP (1) JP5198716B2 (https=)
AT (1) ATE401056T1 (https=)
AU (1) AU2003262146A1 (https=)
CA (1) CA2481187A1 (https=)
DE (1) DE60322200D1 (https=)
GB (1) GB0207899D0 (https=)
WO (1) WO2003086349A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879833B2 (en) * 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
AU2004241746A1 (en) * 2003-05-22 2004-12-02 Nycomed Gmbh Salmeterol and ciclesonide combination
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
WO2004110460A1 (en) * 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
DE102006053374A1 (de) * 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
EP3020393B1 (en) * 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
US10004859B2 (en) 2012-05-09 2018-06-26 Boehringer Ingelheim International Gmbh Atomizer
US20170189329A1 (en) 2014-07-29 2017-07-06 3M Innovative Properties Company Method of preparing a pharmaceutical composition
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物
US12214346B2 (en) 2021-10-13 2025-02-04 Satio, Inc. Dermal patch with a diagnostic test strip
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
US12178979B2 (en) 2021-10-13 2024-12-31 Satio, Inc. Dermal patch for delivering a pharmaceutical
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
US11452474B1 (en) 2021-04-14 2022-09-27 Satio, Inc. Dual lever dermal patch system
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DE19541689A1 (de) * 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
HU219900B (hu) * 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Mért dózist adagoló inhalálóberendezés
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
DE19753301A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von Lactamen
US6264923B1 (en) * 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
BR9911351A (pt) * 1998-06-18 2001-03-13 Boehringer Ingelheim Pharma Formulações farmacêuticas para aerossóis com duas ou mais substâncias ativas
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
JP4672143B2 (ja) * 1998-08-04 2011-04-20 ヤゴテック アーゲー 医薬用エーロゾル製剤
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
HUP0302005A3 (en) * 2000-05-23 2006-07-28 Glaxo Group Ltd Aerosol container for formulations of salmeterol xinafoate

Also Published As

Publication number Publication date
AU2003262146A1 (en) 2003-10-27
JP5198716B2 (ja) 2013-05-15
US20050207984A1 (en) 2005-09-22
EP1492500B1 (en) 2008-07-16
ATE401056T1 (de) 2008-08-15
WO2003086349A1 (en) 2003-10-23
JP2005529102A (ja) 2005-09-29
DE60322200D1 (de) 2008-08-28
EP1492500A1 (en) 2005-01-05
CA2481187A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
GB0207899D0 (en) Formoterol and cielesonide aerosol formulations
PL336885A1 (en) Therapeutic products in the aerosol form
WO2003064387A3 (en) Substituted indoles as alpha-1 agonists
CA2414018A1 (en) 2-aminocarbonyl-9h-purine derivatives
ATE342053T1 (de) Formulierungen zur inhalation
PT1263725E (pt) Novos compostos
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
JO2327B1 (en) Aza andulat
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
ATE316083T1 (de) Adamantanderivate
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
AU2003225915A1 (en) Formoterol and mometasone aerosol formulations
YU87202A (sh) Derivati arilmetilamina koji se koriste kao inhibitori triptaze
GB0109122D0 (en) Novel compounds
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
IL159880A0 (en) Arylsulfonyl derivatives with 5-ht6 receptor affinity
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
DE60008399D1 (de) Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
SE0402925D0 (sv) Novel Compounds
UA95223C2 (ru) Производные пиридопиримидина, их получение, их применение в терапии
TW200510370A (en) Urea derivatives
HUP0004701A2 (hu) Új dezloratadin sók, az ezeket tartalmazó gyógyászati készítmények és eljárás azok előállítására
SE0301371D0 (sv) New Compounds
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
TW200500330A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)